BCL2 and B-cell chronic lymphocytic leukemia: Therapy for CLL has evolved significantly over the past decade with the advent of Bruton Tyrosine Kinase inhibitors and P13K delta inhibitors, alone or combined with a BCL2 inhibitor (venetoclax), superseding the prior standard of conventional chemotherapy given alone or, more commonly, in combination with anti-CD20 antibodies.